KEITH CRANDELL
CIK 1219039 · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$637.27M
Companies
20
Total Filings
74
Lifetime Open-Market Net
$395.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MASS | Director | 5,764,419 | $7.03 | $40.52M | $6.00M | 8 | 2026-06-12 |
| TWST | Director | 103,618 | $88.55 | $9.18M | -$11.52M | 13 | 2026-02-09 |
| NMRA | 10%+ Owner | 6,046,907 | $1.68 | $10.16M | $258.64M | 5 | 2025-10-29 |
| LYEL | 10%+ Owner | 910,317 | $12.99 | $11.83M | $0 | 1 | 2025-07-29 |
| SANA | 10%+ Owner | 12,446,022 | $3.29 | $40.95M | $40.00M | 1 | 2024-02-12 |
| QTRX | Director | 308,483 | $3.49 | $1.08M | $3.99M | 22 | 2023-04-04 |
| VIR | 10%+ Owner | 7,563,619 | $8.85 | $66.94M | $0 | 1 | 2022-09-07 |
| DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Director | 2,250,000 | $10.32 | $23.22M | $16.00M | 2 | 2021-08-09 |
| ADESTO TECHNOLOGIES Corp (IOTS) Delisted | Director | 1,177,937 | — | — | $2.00M | 6 | 2019-06-06 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 435,087 | $0.00 | $174 | -$14.59M | 2 | 2019-03-14 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | 10%+ Owner | 2,900,575 | — | — | $70.39M | 2 | 2019-02-26 |
| PULM | 17,182 | $1.68 | $28.9K | $0 | 1 | 2018-04-05 | |
| Q32 Bio Inc. (FIXX) Delisted | 10%+ Owner | 37,461 | $16.82 | $630.3K | $0 | 1 | 2018-04-04 |
| DNLI | 10%+ Owner | 11,068,749 | $24.05 | $266.20M | $0 | 1 | 2017-12-12 |
| XTERA COMMUNICATIONS, INC. (XCOM) Delisted | 10%+ Owner | — | — | — | $0 | 2 | 2016-10-13 |
| PI | 10%+ Owner | 1,388,049 | $133.03 | $184.65M | $0 | 1 | 2016-07-26 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 3,187,044 | $8.68 | $27.66M | $0 | 1 | 2015-01-16 |
| FATE | 10%+ Owner | 2,473,188 | $2.32 | $5.74M | $25.00M | 1 | 2013-10-07 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | 10%+ Owner | 1,897,474 | — | — | $0 | 1 | 2012-10-16 |
| CELEBRATE EXPRESS, INC. (BDAY) Delisted | Director | — | — | — | $0 | 1 | 2007-10-23 |
Recent Filings · Page 3 of 8
74 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-07-06 | QTRX | Grant (A) | +893 | $15.0K | EDGAR |
| 2022-06-17 | MASS | Mixed | +1,379 | $0 | EDGAR |
| 2022-04-05 | QTRX | Grant (A) | +492 | $15.0K | EDGAR |
| 2022-02-10 | TWST | Grant (A) | +3,491 | $0 | EDGAR |
| 2022-01-05 | QTRX | Mixed | −578,005 | $13.0K | EDGAR |
| 2021-10-05 | QTRX | Mixed | −599,840 | $13.0K | EDGAR |
| 2021-08-13 | TWST | Mixed | −1,022,995 | -$4.82M | EDGAR |
| 2021-08-09 | DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Disp (D) | — | $0 | EDGAR |
| 2021-08-03 | DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Mixed | +2,250,000 | $22.50M | EDGAR |
| 2021-07-06 | QTRX | Mixed | −822,502 | $13.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.